氯吡格雷、华法林及他汀类药物治疗缺血性卒中的遗传药理学研究  

Pharmacogenetics Study of Clopidogrel, Warfarin and Statins in Ischemic Stroke Treatment

作　　者：高一鹭[1] 张拥波[1] 李继梅[1] 

机构地区：[1]北京市首都医科大学附属北京友谊医院神经内科,100050

出　　处：《中国卒中杂志》2011年第11期915-921,共7页Chinese Journal of Stroke

基　　金：北京市卫生系统高层次卫生技术人才培养计划项目(2009-03-07)

摘　　要：抗血小板聚集、抗凝及血脂调控药物是临床治疗与预防缺血性卒中(ischaemic stroke,IS)的重要措施,而氯吡格雷、华法林及他汀类药物是其中常用的治疗药物;然而,遗传因素可导致药物代谢酶、转运体及作用靶点等药物反应相关蛋白活性出现个体差异,从而影响药物的疗效和毒副作用。本文将探讨氯吡格雷、华法林及他汀类药物治疗IS的遗传药理学,并分析影响药物疗效及毒副作用的基因多态性,以利个体化的IS治疗与预防。Anti-platelet aggregation, coagulation and lipid regulation are the important measures of clinical treatment and prevention of ischemic stroke（IS）. Clopidogrel, warfarin and statins are the commonly used therapy. However, genetic factors that lead to drug metabolizing enzymes, transporters and targets of drug response associated protein for activity individual differences, thus affecting the clinical drug efficacy and toxicity. In this review, we discuss the pharmacogenetics of clopidogrel, warfarin and statins of IS therapy, and analyze the gene polymorphism which affecting the drug efficacy and toxicity to facilitate the individualized treatment and prevention of IS.

关 键 词：脑梗死 遗传药理学 多态现象 遗传 氯吡格雷 华法林 他汀类药物 

分 类 号：R743.3[医药卫生—神经病学与精神病学]